Recruiting Osteogenesis Imperfecta Studies in Berkeley
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical tria...
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with...
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit...
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed...
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL)....
About Osteogenesis Imperfecta Clinical Trials in Berkeley
Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.
There are currently 5 osteogenesis imperfecta clinical trials recruiting participants in Berkeley, CA. These studies are seeking a combined 2,615 participants. Research is being sponsored by National Cancer Institute (NCI), Nexcella Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Osteogenesis Imperfecta Clinical Trials in Berkeley — FAQ
Are there osteogenesis imperfecta clinical trials in Berkeley?
Yes, there are 5 osteogenesis imperfecta clinical trials currently recruiting in Berkeley, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Berkeley?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Berkeley research site will contact you about next steps.
Are clinical trials in Berkeley free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Berkeley studies also compensate for your time and travel.
What osteogenesis imperfecta treatments are being tested?
The 5 active trials in Berkeley are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.
Data updated March 2, 2026 from ClinicalTrials.gov